BioNexus Gene Lab Corp. Payments to Acquire Other Investments
BioNexus Gene Lab Corp. (BGLC) reported Payments to Acquire Other Investments of $6.19 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-16.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireOtherInvestments · last filed 2024-04-16
- BioNexus Gene Lab Corp. payments to acquire other investments for the quarter ending 2023-12-31 was -$289.92K.
- BioNexus Gene Lab Corp. payments to acquire other investments for the quarter ending 2023-09-30 was $282.67K.
- BioNexus Gene Lab Corp. payments to acquire other investments for the quarter ending 2023-06-30 was -$202.00, a 100.09% decline year-over-year.
- BioNexus Gene Lab Corp. payments to acquire other investments for the quarter ending 2023-03-31 was $13.65K, a 92.07% decline year-over-year.
- BioNexus Gene Lab Corp. payments to acquire other investments for fiscal 2023 was $6.19K.
- BioNexus Gene Lab Corp. payments to acquire other investments for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- BioNexus Gene Lab Corp. payments to acquire other investments for fiscal 2021 was $515.84K, a 374.86% increase from fiscal 2020.
- BioNexus Gene Lab Corp. payments to acquire other investments for fiscal 2020 was $108.63K.
| Period end | Payments to Acquire Other Investments 3 month | Payments to Acquire Other Investments 6 month | Payments to Acquire Other Investments 9 month | Payments to Acquire Other Investments 12 month | Payments to Acquire Other Investments 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | -$289.92K derived: 10-K 12 month − 10-Q/A 9 month · filed 2024-04-16 | -$7.25K derived: sum of 2 quarters · filed 2024-04-16 | -$7.45K derived: sum of 3 quarters · filed 2024-04-16 | $6.19K 10-K · filed 2024-04-16 | |
| 2023-09-30 | $282.67K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2024-03-26 | $282.46K derived: sum of 2 quarters · filed 2024-03-26 | $296.11K 10-Q/A · filed 2024-03-26 | -$101.86K derived: sum of 4 quarters · filed 2024-04-16 | |
| 2023-06-30 | -$202.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-16 | $13.44K 10-Q · filed 2023-08-16 | -$384.53K derived: sum of 3 quarters · filed 2024-04-16 | -$391.35K derived: sum of 4 quarters · filed 2024-04-16 | |
| 2023-03-31 | $13.65K 10-Q · filed 2023-05-09 | -$384.33K derived: sum of 2 quarters · filed 2024-04-16 | -$391.15K derived: sum of 3 quarters · filed 2024-04-16 | -$158.53K derived: sum of 4 quarters · filed 2024-04-16 | |
| 2022-12-31 | -$397.97K derived: 10-K 12 month − 10-Q/A 9 month · filed 2024-04-16 | -$404.79K derived: sum of 2 quarters · filed 2024-04-16 | -$172.17K derived: sum of 3 quarters · filed 2024-04-16 | $0.00 10-K · filed 2024-04-16 | $511.71K 10-K · filed 2023-03-31 |
| 2022-09-30 | -$6.82K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2024-03-26 | $225.80K derived: sum of 2 quarters · filed 2024-03-26 | $397.97K 10-Q/A · filed 2024-03-26 | $481.52K derived: sum of 4 quarters · filed 2024-03-26 | |
| 2022-06-30 | $232.62K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-16 | $404.79K 10-Q · filed 2023-08-16 | $488.34K derived: sum of 3 quarters · filed 2023-08-16 | $548.87K derived: sum of 4 quarters · filed 2023-08-16 | |
| 2022-03-31 | $172.17K 10-Q · filed 2023-05-09 | $255.72K derived: sum of 2 quarters · filed 2023-05-09 | $316.25K derived: sum of 3 quarters · filed 2023-05-09 | $391.99K derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $83.55K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $144.08K derived: sum of 2 quarters · filed 2023-03-31 | $219.81K derived: sum of 3 quarters · filed 2023-03-31 | $515.84K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $60.53K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $136.27K derived: sum of 2 quarters · filed 2022-11-14 | $432.29K 10-Q · filed 2022-11-14 | $433.14K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $75.73K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $371.76K 10-Q · filed 2022-08-15 | $372.61K derived: sum of 3 quarters · filed 2022-08-15 | $371.26K derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | $296.02K 10-Q · filed 2022-05-16 | $296.87K derived: sum of 2 quarters · filed 2022-05-16 | $295.53K derived: sum of 3 quarters · filed 2022-05-16 | $303.16K derived: sum of 4 quarters · filed 2022-05-16 | |
| 2020-12-31 | $846.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-06 | -$495.00 derived: sum of 2 quarters · filed 2022-04-06 | $7.13K derived: sum of 3 quarters · filed 2022-04-06 | $108.63K 10-K · filed 2022-04-06 | |
| 2020-09-30 | -$1.34K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $6.29K derived: sum of 2 quarters · filed 2021-11-15 | $107.78K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $7.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $109.13K 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $101.50K 10-Q · filed 2021-05-18 | ||||
| 2019-12-31 | $0.00 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |